Deutsche Bank analyst David Hoang initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $176 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent litigation related to Axsome’s AUVELITY product. The ...

Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a decade. Axsome, maker of the ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ...

Axsome Therapeutics, Inc. NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Analysts across Wall Street raised their price targets for Axsome. The upgrades came after news broke that the company had settled a key lawsuit. A senior analyst at the Japanese banking giant ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports.

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $143. ...